arrow
K

Katherine Lajkosz

university health network toronto
H指数:24
被引数:2,112

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

THE SUMMIT STUDY: A REAL-WORLD, PROSPECTIVE, MULTI-CENTER STUDY TO EVALUATE THE PERFORMANCE OF THE OPTILUME BPH CATHETER SYSTEM IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)

巅峰研究:一项真实世界、前瞻性、多中心研究,旨在评估OPTILUME BPH导管系统在症状性良性前列腺增生(BPH)男性患者中的表现

2026-05-010
PRE
Reply to Dr. Zhang’s Letter to the Editor re: R.M. Bernardino, L.B. Yin, K. Lajkosz, et al. Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial. Eur Urol Open Sci 2025;82:52–8

回复张博士致编辑函,关于:R.M. Bernardino, L.B. Yin, K. Lajkosz, et al. 高风险前列腺癌中导管内癌预测新辅助治疗反应不佳:一项前瞻性试验的回顾性分析。Eur Urol Open Sci 2025;82:52–8

2026-04-270
OAAI
Development of a preoperative risk prediction model of muscleinvasive upper tract urothelial carcinoma using clinical and radiomic computed tomography features: Initial results from a multi-institutional, Canadian study

基于临床和放射组学计算机断层扫描特征的肌肉浸润性上尿路尿路上皮癌术前风险预测模型的开发:一项多中心加拿大研究的初步结果

2026-04-010
PRE
Rezūm therapy: Outcomes of symptom relief and quality of life in benign prostatic obstruction with three-year followup

Rezūm疗法:治疗良性前列腺梗阻三年随访的症状缓解和生活质量结果

2026-04-010
PRE
Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial

导管内癌预示高危前列腺癌对新辅助疗法的反应不佳:一项前瞻性试验的回顾性分析

2025-10-140
OAAI
Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer

基于人工智能的模型(PROGRxN-BCa)的开发与国际评估:使用世界卫生组织2004/2022分级系统预测进展风险并改善非肌层浸润性膀胱癌的亚分层

2025-10-070
PRE
Corrigendum to “Magnetic Resonance Imaging (MRI)–Adapted Prostate Cancer Risk Tool Incorporating Cribriform and Intraductal Carcinoma” (Modern Pathology 2025 Dec;38(12):100852)

勘误:“Magnetic Resonance Imaging (MRI)–Adapted Prostate Cancer Risk Tool Incorporating Cribriform and Intraductal Carcinoma”(Modern Pathology 2025 Dec;38(12):100852)

2025-10-070
PRE
MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses

微小RNA作为液体生物标志物,用于检测小睾丸肿块的恶性程度

2025-09-250
PRE
Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience

接受镭223治疗的具有和不具有同源重组缺陷(HRD)的转移性去势抵抗性前列腺癌(mCRPC)男性的生存结局:Princess Margaret Cancer Centre(PMCC)经验

2025-09-010
PRE